Literature DB >> 7656755

Utility of cytokeratin 20 in identifying the origin of metastatic carcinomas in effusions.

V Ascoli1, S Taccogna, C C Scalzo, F Nardi.   

Abstract

Using a commercially available monoclonal antibody (Ks20.1) and the avidin-biotin peroxidase method on cytospins and cell blocks, we analyzed cytokeratin (CK) 20 expression in 169 serous effusions. Cytoplasmic staining was observed in 44/151 malignant fluids. Colon, gastric, and pancreatic adenocarcinomas and mucinous ovarian tumors were most frequently positive. Single cases of transitional-cell and squamous cell carcinomas were reactive as well. Lung and breast cancers were mostly negative. Nonmucinous ovarian tumors were invariably unlabeled as were mesotheliomas and normal mesothelial cells. The study shows that CK 20 is valuable in distinguishing tumor cell origin in effusions. In particular, it identifies a set of carcinomas with the majority arising from the gastrointestinal tract, and represents a highly characteristic marker for colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7656755     DOI: 10.1002/dc.2840120404

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  3 in total

1.  E-cadherin and cytokeratin subtype profiling in effusion cytology.

Authors:  Joungho Han; Mi-Kyung Kim; Seok-Jin Nam; Jung-Hyun Yang
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

2.  Increased plasma microRNA and CD133/CK18-positive cancer cells in the pleural fluid of a pancreatic cancer patient with liver and pleural metastases and correlation with chemoresistance.

Authors:  Chuanli Ren; Hui Chen; Chongxu Han; Daxin Wang; Deyuan Fu
Journal:  Oncol Lett       Date:  2012-07-13       Impact factor: 2.967

Review 3.  Serous cavity metastasis: Evaluation of unknown primary.

Authors:  Nirag Jhala; Aileen Arriola; Liron Pantanowitz
Journal:  Cytojournal       Date:  2022-03-19       Impact factor: 2.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.